Open Badges Letter

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors

Alma Carracedo123, Kristof Egervari4, Marta Salido13, Federico Rojo567, Josep M Corominas5, Montserrat Arumi568, Cristina Corzo9, Ignacio Tusquets10, Blanca Espinet13, Ana Rovira6, Joan Albanell106, Zoltan Szollosi4, Sergi Serrano5 and Francesc Solé13*

Author Affiliations

1 Servei de Patologia, Laboratori de Citogenètica Molecular, Hospital del Mar, IMAS, GRETNHE, IMIM, 08003 Barcelona, Spain

2 Departament de Biologia Cellular, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain

3 Escola de Citologia Hematològica S Woessner-IMAS, 08003 Barcelona, Spain

4 Department of Pathology, University of Debrecen MHSC, 4032 Debrecen, Hungary

5 Servei de Patologia, Unitat de Patologia Mamària, Hospital del Mar, UAB, 08003 Barcelona, Spain

6 Molecular Therapeutics and Biomarkers in Breast Cancer Program, IMIM-Hospital del Mar, 08003 Barcelona, Spain

7 Capio-Fundación Jiménez Díaz, 28040 Madrid, Spain

8 Department of Health and Experimental Sciences, Universitat Pompeu Fabra, 08003 Barcelona, Spain

9 Escola Bonanova-IMAS, 08003 Barcelona, Spain

10 Oncology Department, Hospital del Mar, 08003 Barcelona, Spain

For all author emails, please log on.

Breast Cancer Research 2009, 11:402  doi:10.1186/bcr2239

See related research article by Götte et al.,

The electronic version of this article is the complete one and can be found online at:

Published:21 April 2009

© 2009 BioMed Central Ltd


In their report, Götte and coworkers [1] analyzed the expression of c-Met in 200 patients with ductal carcinoma in situ. They concluded that c-Met could be related to angiogenic and lymphangiogenic factors in ductal carcinoma in situ. On the other hand, Greenberg and coworkers [2] studied 31 patients with ductal infiltrating carcinoma (DIC) to detect c-Met expression in their axillary fluids. They observed a correlation of c-Met expression with increasing tumor size and grade, capillary and lymphatic invasion and lymph node metastasis.

We applied the fluorescent in situ hybridization (FISH) technique using the LSI D7S486/CEP7 commercial probe (Abbott Molecular Inc., Des Plaines, IL, USA), which includes the MET gene, and immunohistochemistry using c-Met monoclonal antibody clone 3D4 (Invitrogen, Carlsbad, CA, USA) to 184 archival invasive breast tumors (93 DIC and 91 lobular carcinomas). We constructed ten tissue microarrays with three replicates per sample. Pearson's chi-squared and Fisher's exact test were used to analyze the results.

None of the 155 breast tumors analyzed by FISH presented amplification of MET and 35 cases (22%) had a low grade of polysomy (three to five copies) of chromosome 7. Polysomy was more frequently observed in DIC (25%; P = 0.001). We tried to correlate polysomy of MET in the DIC group with grade, tumor size, lymph node status, clinical stage and expression of HER2, P53, estrogen receptor (ER) and progesterone receptor (PR). We observed that the absence of expression of PR was the unique statistically significant variable (P = 0.001). Moreover, the ER+/PR- samples presented the highest rate of polysomy (38%) compared to ER+/PR+ tumors (15%) (Table 1).

Table 1. Results of IHC of c-Met and FISH of LSI D7S486/CEP7 applied to lobular and ductal carcinomas

Out of 168 tumors analyzed by immunohistochemistry, 65 (38.7%) presented expression of c-Met. When histological types were compared, the DIC group also showed the highest number of c-Met-positive samples (48%; P = 0.001). From the analysis with the clinico-pathological variables, the negativity for PR was again statistically significant (P = 0.001). The ER+/PR- tumors presented more frequent expression of c-Met (68%) compared to ER+/PR+ tumors (32%) and were correlated with polysomy (P = 0.020) (Table 2).

Table 2. IHC and FISH results of MET according to the status of PR receptor in DIC carcinomas

We can conclude that amplification of MET in breast cancer is not a common event, as opposed to other cancer subtypes (renal, gastric and lung carcinomas). Although found in breast tumors, it seems that overexpression of c-Met is not mainly due to increassed gene copy number of MET/polysomy7. However, polysomy in the ER+/PR- group could be an important mechanism – although not the only one – responsible for the differential expression observed in this type of DIC. This c-Met overexpression and the presence of polysomy 7 could be important events to be considered with regard to the known poor response to endocrine therapies of ER+/PR- breast tumors. Lack of PR expression in ER+ tumors may be a surrogate marker of aberrant growth factor signaling [3] that could be associated with their more aggressive outcome, as has already been described [4].

Our study suggests that it would be interesting to investigate new therapeutic options for ER+/PR- DIC, which may include c-Met inhibitors.


DIC: ductal infiltrating carcinoma; ER: estrogen receptor; FISH: fluorescent in situ hybridization; PR: progesterone receptor.

Competing interests

The authors declare that they have no competing interests.


Grants PI05/0961 and PI06/1513 from Ministerio de Sanidad y Consumo ISCIII and RTICC 06/0020/19. Tumoral samples belong to the 'Xarxa de Banc de Tumors de Catalunya' (XBTC).


  1. Götte M, Kersting C, Radke I, Kiesel L, Wülfing P: An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ.

    Breast Cancer Res 2007, 9:R8. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  2. Greenberg R, Schawartz I, Skornick Y, Kaplan O: Detection of hepatocyte growth factor/scatter factor repector (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reaction.

    Breast Cancer Res 2003, 5:R71-R76. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  3. Creighton CJ, Osborne K, Vijver MJ, Foekens JA, Klin JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chammess GC, Hilsenbeck SG, Lee AV, Schiff R: Molecular profiles of progesterone receptor loss in human breast tumors.

    Breast Cancer Res Treat 2009, 114:287-299. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  4. Arpino G, Weiss H, Lee VA, Schiff R, De Placido S, Osborne K, Elledge RM: Estrogen receptor-positive, progesterone receptor-negative breast cancer; association with growth factor receptor expression and tamoxifen resistance.

    J Natl Cancer Inst 2005, 97:1254-1261. PubMed Abstract | Publisher Full Text OpenURL